This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by SoRelle, R. Search for Related Content PubMed Articles by SoRelle, R.

(Circulation. 2001;104:e9022.)
© 2001 American Heart Association, Inc.

News From the European Society of Cardiology Congress XXIII

Ruth SoRelle, MPH

Circulation Newswriter

The XXIII Congress of the European Society of Cardiology opened to cool blue skies in Stockholm, Sweden, on September 1, 2001, as >20 000 cardiologists, scientists, and other healthcare providers gathered for the largest heart-related meeting on the continent. With "Hotline" sessions spotlighting the latest research spanning 3 days, the Congress drew large morning crowds to hear their colleagues explain the newest studies.

Those spotlighted included:

ESCAMI
On September 1, 2001, the day before scientific presentations began, Martin Simoons, MD, president of the European Society of Cardiology, predicted the results reported at the first Hotline for the newest information would change the way he and his staff treat acute myocardial infarction. After the session on September 2, 2001, he said he would add the use of low-molecular-weight heparin to his armamentarium.

Uwe Zeymer, MD, of the Staedtische Kliniken in Kassel, Germany, reported that the sodium hydrogen exchange inhibitor eniporide did not add to the positive effects of thrombolysis in patients with acute myocardial infarctions. His trial, the Evaluation of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI), involved 2 stages. The first was designed to prove efficacy and safety and to select 2 doses for the second stage of the trial. The stage 2 part of the trial was designed to select the dose for a large-scale mortality trial. In that trial, 320 patients in each group received placebo, 100 mg of eniporide, or 150 mg of eniporide (the 2 doses chosen from phase 1).

In the . . . [Full Text of this Article]